FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Use Restrictions on Drug Promo Launch Materials Under Review

[ Price : $8.95]

FDA says drug marketers should not use the same or similar claims contained in voluntarily submitted product launch advertising an...

New Critical Path Institute Head Known Soon

[ Price : $8.95]

Retiring Critical Path Institute director Raymond Woosley says his successor should be announced by next month.

Genentech Agrees to Pay $20 Million in Whistleblower Suit

[ Price : $8.95]

Genentech agrees to pay $20 million to settle claims in a whistleblower lawsuit that alleges the company promoted Rituxan (rituxim...

FDA Lipitor Petition Denial Posted

[ Price : $8.95]

FDA posts a petition rejection letter dismissing Pfizer attempts to delay the introduction of generic Lipitor (atorvastatin) produ...

FDA OKs Mylan ANDA for Hemophilia

[ Price : $8.95]

FDA approves a Mylan ANDA for tranexamic acid injection, a generic version of Pharmacia & Upjohns Cycklokapron injection, indicate...

Woodcock: Coming of Age for Speedier Drugs Consortia

[ Price : $8.95]

CDER director Janet Woodcock says we have reached a coming of age for the multiple consortia around the world working on different...

Hamburg: Regulatory Science Undervalued

[ Price : $8.95]

Commissioner Margaret Hamburg says she fears the field of regulatory science remains undervalued and underdeveloped as an importan...

Did FDA Lose Leverage in Approving Ranbaxy Generic Lipitor?

[ Price : $8.95]

FDA and federal prosecutors seem to have passed up a huge leverage opportunity to win a settlement and resolve outstanding issues ...

Dietary Supplement Firms and Owners Sentenced for Contempt

[ Price : $8.95]

A New Jersey federal judge gives three men jail time for violating a consent decree to close their dietary supplement manufacturin...

NPS Finishes Gattex NDA Submission

[ Price : $8.95]

NPS Pharmaceuticals says it has completed submitting a Gattex NDA and has asked FDA for a priority review.